{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:51:22Z","timestamp":1791960682333,"version":"4.3.4"},"reference-count":17,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,4,1]],"date-time":"2016-04-01T00:00:00Z","timestamp":1459468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2016,4]]},"DOI":"10.1016\/j.jcjo.2015.11.007","type":"journal-article","created":{"date-parts":[[2016,4,13]],"date-time":"2016-04-13T10:53:05Z","timestamp":1460544785000},"page":"91-96","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment of CNV secondary to presumed ocular histoplasmosis with intravitreal aflibercept 2.0 mg injection"],"prefix":"10.1016","volume":"51","author":[{"given":"Harpreet S.","family":"Walia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav K.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin J.","family":"Blinder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2015.11.007_bib1","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1016\/S0161-6420(84)34113-6","article-title":"Subfoveal and juxtafoveal subretinal neovascularization in the presumed ocular histoplasmosis syndrome","volume":"91","author":"Olk","year":"1984","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2015.11.007_bib2","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/00006982-198808040-00001","article-title":"Subfoveal neovascularization in the ocular histoplasmosis syndrome: a natural history study","volume":"8","author":"Kleiner","year":"1988","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2015.11.007_bib5","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1001\/archopht.126.12.1626","article-title":"Surgical removal vs observation for idiopathic or ocular histoplasmosis syndrome-associated subfoveal choroidal neovascularization: Vision Preference Value Scale findings from the randomized SST Group H Trial: SST Report No.17","volume":"126","author":"Bass","year":"2008","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.11.007_bib6","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1001\/archopht.122.11.1597","volume":"122","author":"Hawkins","year":"2004","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.11.007_bib7","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1001\/archopht.1997.01100160161004","article-title":"Submacular surgery for subfoveal choroidal neovascular membranes in patients with presumed ocular histoplasmosis","volume":"115","author":"Berger","year":"1997","journal-title":"Arch Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.11.007_bib8","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/S0161-6420(94)31172-9","article-title":"Visual results after surgical removal of subfoveal choroidal neovascular membranes","volume":"101","author":"Thomas","year":"1994","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2015.11.007_bib9","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S0161-6420(97)30367-4","article-title":"Surgical removal of subfoveal choroidal neovascularization in presumed ocular histoplasmosis: stability of early visual results","volume":"104","author":"Holekamp","year":"1997","journal-title":"Ophthalmology"},{"key":"10.1016\/j.jcjo.2015.11.007_bib10","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1097\/00006982-200501000-00003","article-title":"Photodynamic therapy for juxtafoveal chorodial neovascularization due to ocular histoplasmosis syndrome","volume":"25","author":"Shah","year":"2005","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2015.11.007_bib11","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00006982-200306000-00003","article-title":"Ocular photodynamic therapy with verteporfin for choroidal neovascularization secondary to ocular histoplasmosis syndrome","volume":"23","author":"Busquets","year":"2003","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2015.11.007_bib12","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.ajo.2007.12.030","article-title":"Intravitreal bevacizumab for choroidal neovascularization in ocular histoplasmosis","volume":"145","author":"Schadlu","year":"2008","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.11.007_bib13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3928\/23258160-20121221-07","article-title":"Ranibizumab versus photodynamic therapy for presumed ocular histoplasmosis","volume":"44","author":"Ramaiya","year":"2013","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.jcjo.2015.11.007_bib14","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0002-9394(03)00389-1","article-title":"Intravitreal triamcinolone for choroidal neovascularization in ocular histoplasmosis syndrome","volume":"136","author":"Rechtman","year":"2003","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.jcjo.2015.11.007_bib15","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1089\/jop.1999.15.425","article-title":"Corticosteroids as an antiangiogenic agent for histoplasmosis-related subfoveal choroidal neovascularization","volume":"15","author":"Martidis","year":"1999","journal-title":"J Ocul Pharmacol Ther"},{"key":"10.1016\/j.jcjo.2015.11.007_bib16","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1097\/00006982-200412000-00004","article-title":"Photodynamic therapy of subfoveal and juxtafoveal choroidal neovascularization in ocular histoplasmosis syndrome: a retrospective case series","volume":"24","author":"Liu","year":"2004","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2015.11.007_bib17","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1097\/IAE.0b013e318229b220","article-title":"Intravitreal anti-vascular endothelial growth factor therapy for choroidal neovascularization secondary to ocular histoplasmosis syndrome","volume":"32","author":"Nielsen","year":"2012","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2015.11.007_bib18","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/IAE.0b013e3181babdf1","article-title":"Intravitreal bevacizumab for choroidal neovascularization secondary to presumed ocular hisotplasmosis syndrome","volume":"29","author":"Ehrlich","year":"2009","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2015.11.007_bib19","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ophtha.2011.08.032","article-title":"Analysis of outcomes for intravitreal bevacizumab in the treatment of chorodial neovascularization secondary to ocular histoplasmosis","volume":"119","author":"Cionni","year":"2012","journal-title":"Ophthalmology"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418215004846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418215004846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T20:04:59Z","timestamp":1757793899000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418215004846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4]]},"references-count":17,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,4]]}},"alternative-id":["S0008418215004846"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2015.11.007","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2016,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment of CNV secondary to presumed ocular histoplasmosis with intravitreal aflibercept 2.0 mg injection","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2015.11.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}